Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia (ITP)

Soochow University

Status: Completed

Conditions: Immune Thrombocytopenic Purpura

Treatments: Drug: rapamycin

Study type: Observational

Funder types: Other

Identifiers

NCT01672151

jsxys456

Details and patient eligibility

About

The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.

Full description

Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients.

Enrollment: 35 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical diagnoses of idiopathic thrombocytopenic purpura
• Hormone and immune suppression, splenectomy is invalid

Exclusion criteria

• patients had a bad tolerance to rapamycin
• platelet counts < 10*10E9/L during the treatment of rapamycin